Veterinary antibiotics API, mostly belonging to products with low added value, variety of aging, but is still indispensable in the global marketplace, but also meet China’s export advantage. At present, the large reduction in the number of veterinary drug enterprises of domestic production, production is concentrated further. In domestic drug sales depressed circumstances, veterinary antibiotics raw materials exports were worth businesses expect.
Increase in industry concentration, improved market competition order
Veterinary antibiotics is currently the most widely used antibiotics in products, as well as exports of one of the largest categories of antibiotics, its size is much larger than people with antibiotics.
As people increasingly concerned about food safety, people’s safety for veterinary medicinal products is of growing concern. 2005, Ministry of Agriculture began forced implementation veterinary drugs production quality management specification (following referred to veterinary drugs GMP); 2006, full completed has on production veterinary drugs of enterprise for of GMP certification, eliminated has large not qualified enterprise, while also abolished has veterinary drugs place standard, unified used national standards, and abolished has some will produced resistance drug, and led to drug residues and lack security effective experiment data of drug and group party not reasonable, and efficacy not exact of compound preparations. After consolidation, reduced number of veterinary drug enterprises of domestic production by about two-thirds, production concentration increased market competition has improved.
Bulk exports of veterinary antibiotics accounted for mainstream and hot varieties in short supply
In the export of veterinary antibiotics, bulk exports of veterinary antibiotics still dominate. According to health statistics: in 2006, the tetracycline class both in terms of export volume in the export payments, were ranked first in the export of veterinary antibiotics; products, Chloramphenicol and derivatives with many more sales.
In 2006, China’s export volume of top 10 varieties of veterinary antibiotics are: terramycin, bacitracin Zinc salt, and bleomycin, tetracycline hydrochloride, doxycycline, colistin sulphate bacilli, and Tylosin, yellow-mycin and streptomycin sulfate and neomycin sulfate. Among them, export of veterinary antibiotics is hot with many varieties, such as Bacillus of colistin sulphate, and Tylosin, florfenicol, fumaric acid Tai Miao Streptozotocin, tilmicosin, etc. In particular, many pharmaceutical companies
Industry won EU COS certification of sticky Bacillus sulfate, which expand our exports of this product, improve product value-added highly favourable. Because of competitive reasons, 2006, colistin sulphate Bacillus grain prices way down. The beginning of 2007, prices dip back, is still on the rise. Although domestic production of sticky Bacillus sulfate businesses more, but because some enterprises to stop production or output, current supply of sticky Bacillus sulfate
Are tense and the situation is likely to continue for some time.
In recent years, veterinary tylosin has been a hot spot of China’s exports. Tilmicosin since 2004, its derivatives the foreign manufacturers after patents expire, enterprises have launched this product in China, but so far, tilmicosin in China’s export volume has been modest, and most of the companies do not have consecutive export record. However, tilmicosin of veterinary in 2006, exports rose faster. Worthy of note is the currently registered in the Ministry of agriculture for the
Tilmicosin production only a dozen, but the actual production of this product with no less than 30, and meter manufacturers will inevitably test star facing “shuffle the cards”.
In 2006, the animal uses fumaric acid Miao Streptozotocin, Thai exports also achieved a breakthrough, cumulative exports 129 tons, total exports worth 850,000 dollars. The current drop in prices has been relatively good, but the stage of its life cycle is still on the rise in the domestic market.
South American markets open in Southeast Asia, the EU market in North America is still limited
Veterinary medicines in China into Southeast Asia’s threshold is relatively low, so that domestic enterprises to explore the international market, generally preferred access to markets such as Southeast Asia, South Asia and Latin America, while North American and European markets set up obstacles that companies find it difficult to enter.
Since 2006, the EU comprehensive antibiotic feed additives. In 2005, China’s export to the European Community for the last 4 kinds of antibiotic additive salinomycin sodium, yellow lincomycin, monensin, caring little for Adriamycin, and in 2006 by the European Union to prohibit use of edible animal feed additives. However, as these antibiotics are still used in veterinary medicine, so part of these types of products are still sold to EU countries. Despite entering the European and American markets with more restricted, but exports to Europe and North America can achieve relatively high profit, thus, developing these two still have many companies working toward the mainstream market.
Health statistics show that in 2006, veterinary antibiotics in this country are exported to Brazil and the United States, and India, and Germany and the Netherlands, and Malaysia, and Colombia, and Mexico, and Belgium, and Spain.
Editor:
Hospital Clinic antibiotics abuse, make the antibiotics that had been on the market for human use RSVPs celebrities became “out-of-date”, and some antibiotics production enterprise and therefore never recovered. Veterinary antibiotics in demand in the international market, so that these enterprises before–this is a good way. In fact, some antibiotics, pharmaceutical companies have already started to explore the international veterinary markets. But it need to be reminded that a recent
Two years of constant exposure of the domestic food safety issues–from lean and Malachite Green to turbot, one associated with veterinary drugs, and developed the “green barrier” is only going to build more high on residues of veterinary drugs in food issues will be more strictly controlled. It can be said that veterinary drug market opportunities, but also challenging.
Nevertheless, judging from the present market, veterinary antibiotics over a long period of time will still be the mainstream veterinary drug products, high security, low residue, low-resistant varieties, is a more promising, and this should arouse the attention of antibiotic production enterprises in China. This article from the author of the health network: Lee yo won; Wu Huifang
